Companies › Baxis Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 3; Infectious disease.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Fusidic Acid 1% Bacterial protein synthesis inhibitor targeting elongation factor G | FUSE | Phase 3 | Bacterial Conjunctivitis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06911424 | Fusidic Acid 1% | Phase 3 | Bacterial Conjunctivitis | Infectious disease | Mar 2026 |
–
TCM Biotech International Vivacelle Bio Ansun Biopharma SymBio Pharmaceuticals F2G
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.